Fulfilling the Promise of Biosimilars

Biosimilar medicines have the potential to foster unprecedented access to several vital biologics used to treat serious diseases such as rheumatoid arthritis and cancer – coming off patent by the end of the decade. Recent studies show considerable variations in policy across the EU, translating into heterogeneous uptake of biosimilars in EU Member States. To foster greater equity in access to these life-changing therapies, three key enablers are needed: trust in biosimilars, sustainable market policies, and predictable legal and regulatory environments.

We continue to see concerns being raised about biosimilars among patients and health…